• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Computational Model Identifies TPI1 as Ovarian Cancer Target

by
November 10, 2026
in Cancer, Health
Reading Time: 6 mins read
0
Computational Model Identifies TPI1 as Ovarian Cancer Target

Computational Model Identifies TPI1 as Ovarian Cancer Target

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Researchers at the University of Manchester have developed a computational workflow that identifies specific metabolic vulnerabilities in ovarian cancer cells, with experimental validation confirming the role of the enzyme triosephosphate isomerase 1 (TPI1) in cell survival. Published in Cancer & Metabolism, the study demonstrates that constraint-based modelling (CBM), a method that reconstructs cellular metabolism using genomic and transcriptomic data, can accurately predict which genes are essential for the proliferation of cancer cell lines. By integrating high-throughput ‘omics data with genome-scale metabolic models, the team created a framework that not only predicts proliferation rates but also identifies potential therapeutic targets for in vitro validation.

Ovarian cancer remains a significant clinical challenge, accounting for approximately 4.4% of all cancer-related deaths in women, with a 5-year survival rate of only 29% due to frequent late diagnosis. The majority of these tumours are of epithelial origin and are treated with cytoreductive surgery and platinum-based chemotherapy. However, the efficacy of these treatments is often limited by chemoresistance, which results in a recurrence risk of at least 60%. This clinical reality underscores the urgent need for novel, mechanism-based approaches to therapeutic discovery that can address the metabolic reprogramming characteristic of cancer cells.

The study utilised a recently developed single-omics integration algorithm to constrain 47 individual metabolic models using publicly available gene expression data from the Cancer Cell Line Encyclopedia (CCLE). These models were built upon the Human1 genome-scale metabolic model, where transcriptomic data was integrated with gene-protein-reaction rules to place boundaries on reaction rates. This process transforms the unconstrained solution space into a biologically relevant representation, allowing for the estimation of flux distributions via flux balance analysis. The goal was to create sample-specific models that could serve as scaffolds for in silico genetic engineering simulations.

To verify the accuracy of these computational models, the researchers compared the predicted proliferation rates with experimental doubling times measured in vitro. The analysis revealed a significant positive correlation, with a Pearson correlation coefficient of 0.5386 and a p-value less than 0.0001. This agreement between the model predictions and experimental measurements provided the foundation for using these metabolic models as platforms to study the inhibition of ovarian cancer cell lines through simulated gene deletions.

The team focused on serous subtypes, the most prevalent form of epithelial ovarian cancer, and narrowed their analysis to 17 cell line models that were included in the CCLE CRISPR-Cas9 gene dependency dataset. By simulating the deletion of 3,628 enzyme-encoding genes, the models identified 760 genes whose removal would reduce cell proliferation by at least 5%. Of these, 715 genes were present in the experimental dataset, allowing for a direct correlation between in silico predictions and experimental gene dependency scores. Thirteen of the 17 models showed a significant correlation with the experimental data, indicating their reliability for predicting the effects of gene knockdown.

From this subset, the researchers applied four qualitative criteria to select a single target for experimental exploration: consistency of the proliferation effect across models, the avoidance of complete proliferation inhibition to ensure sufficient material for RNA sequencing, a ‘titratable’ effect that allows for partial knockdown, and high protein expression across ovarian cell lines. TPI1 emerged as the most promising candidate, demonstrating a standard deviation of less than 10% in predicted proliferation effect, compared to 15% and 24% for alternative ATP synthase targets. Additionally, TPI1 showed higher expression levels in the CCLE dataset and a smoother decline in proliferation rate during simulated partial knockdown.

Experimental validation was performed using the OV56 serous adenocarcinoma cell line, which was chosen because it was not part of the initial target prediction panel, thus testing the broader applicability of the model. siRNA-mediated knockdown of TPI1 reduced colony formation to approximately 20% of the control levels, a result comparable to the knockdown of the MYC oncogene. While short-term proliferation ratios were variable, longer-term colony formation assays confirmed the dependency of the OV56 cell line on TPI1 for survival, supporting the computational predictions.

RNA sequencing analysis of the TPI1 knockdown samples revealed a significant disruption in gene expression, with 2,419 genes upregulated and 2,584 genes downregulated. Functional enrichment analysis indicated that the knockdown inhibited proliferation, migration, and invasion while promoting cellular apoptosis. The data suggested that TPI1 knockdown downregulates integrin cell surface interactions and protein kinase A signalling, while activating the PPAR signalling pathway. These molecular changes provide a mechanistic basis for the observed reduction in cell survival and proliferation.

As a final validation step, the RNA sequencing data from the experimental knockdown was integrated back into the metabolic model to compare the ‘real-world’ metabolic state with in silico gene deletion simulations. The ‘real-world’ TPI1 knockdown model showed the highest similarity to the in silico TPI1 deletion model, with an accuracy score of 0.619, significantly higher than the mean score of 0.375 for other gene deletions. This result rejected the null hypothesis and demonstrated that constraint-based modelling can accurately predict not only the proliferation effect but also the metabolic flux distribution of a gene knockdown.

The study proposes a speculative mechanistic model for TPI1 in ovarian cancer, linking its activity to the regulation of E-cadherin and MDM2. The researchers suggest that reducing TPI1 expression may maintain cell-cell adhesion and remove negative regulation of the p53 tumour suppressor, thereby exerting a tumour-suppressive effect. Although the findings are based on cell line models and require further validation in patient-derived systems, the workflow provides a translatable framework for identifying metabolic targets in other malignancies. This approach highlights the potential of integrating computational modelling with experimental biology to uncover novel therapeutic vulnerabilities in cancer metabolism.

The constraint-based modelling workflow described in this study relies on the Human1 genome-scale metabolic model, which contains 3,628 enzyme-encoding genes. By integrating transcriptomic data from the Cancer Cell Line Encyclopedia, the researchers placed specific boundaries on reaction rates, transforming an unconstrained computational space into a biologically relevant representation. This integration allows for the estimation of flux distributions using flux balance analysis, where biomass production serves as the objective function. The single-omics integration algorithm used in this work guides the acceptance or rejection of gene expression measurements based on experimental proliferation measurements, ensuring that the resulting models reflect realistic cellular phenotypes. This approach enables the simulation of genetic engineering outcomes, such as gene deletions, to predict how specific metabolic perturbations might influence cell survival in a controlled in silico environment.

While the primary focus of the study was on ovarian cancer, the authors note that constraint-based modelling has been successfully applied to other disease contexts. For instance, similar computational approaches have facilitated the metabolic subtyping of endometrial cancer and the identification of subtype-specific essential genes in colorectal cancer. The methodology has also been employed in drug repurposing projects, such as predicting existing drugs that could reverse gene expression changes associated with prostate cancer. Beyond oncology, constraint-based modelling has been utilized to study antibacterial resistance and to optimize the production of monoclonal antibodies in chemical engineering. These diverse applications underscore the broad utility of the workflow presented here, which serves as a framework for future discovery projects across various fields of systems biology.

The experimental validation of the model predictions was conducted using the OV56 serous adenocarcinoma cell line and the A549 lung adenocarcinoma cell line. The OV56 line was specifically selected because it was not included in the initial panel of models used for target prediction, thereby testing the generalizability of the computational framework. In the A549 line, TPI1 knockdown was previously reported to reduce colony formation and cell proliferation, providing a relevant comparison for the ovarian cancer context. The researchers used siRNA-mediated transfection to achieve knockdown, with immunoblotting confirming that TPI1 protein levels were reduced to approximately 14% and 40% of initial expression in two replicates. This level of knockdown was sufficient to observe significant changes in cellular behavior, including the formation of smaller and fewer colonies over a ten-day period.

RNA sequencing analysis revealed that TPI1 knockdown significantly altered the transcriptome of the OV56 cell line. Out of 33,253 genes with nonzero read counts, 15% were differentially regulated, with 2,419 genes upregulated and 2,584 downregulated. The top differentially expressed genes included EMC10, PLBD2, and SIGMAR1. Functional enrichment analysis indicated that the knockdown was associated with the inhibition of cellular proliferation, migration, and invasion, while promoting apoptosis. These findings align with the observed reduction in colony formation and suggest that TPI1 plays a critical role in maintaining the proliferative capacity of ovarian cancer cells. The disruption of cellular homeostasis observed in the RNA sequencing data further supports the notion that TPI1 is integral to the metabolic stability of these cells.

The study acknowledges several limitations, including the reliance on cell line models that may undergo genetic drift during extensive culture. The authors suggest that future studies should validate these findings using ex vivo patient-derived models or patient-derived xenografts to better capture the heterogeneity of ovarian cancer. Additionally, the proposed mechanistic model for TPI1 is speculative, based on co-mention with TPI1 in other cancer types rather than direct evidence of interaction in ovarian cancer. The complex and sometimes counter-intuitive gene expression patterns observed, such as the upregulation of AKT1 and AKT3 alongside the downregulation of MTOR, highlight the adaptive nature of cancer cells and the need for further investigation into the specific interactions of TPI1 in this context.

Subject of Research: Constraint-based modelling and experimental validation of TPI1 as a metabolic target in ovarian cancer

Article Title: Transcriptome-driven constraint-based modelling reveals metabolic targets for ovarian cancer

Article References: Meeson, K. E., McGrail, J. C., Schwartz, J.-M., & Taylor, S. S. (2026). Transcriptome-driven constraint-based modelling reveals metabolic targets for ovarian cancer. Cancer & Metabolism, 14(1), Article 7. https://doi.org/10.1186/s40170-026-00425-6

Image Credits: AI Generated

DOI: 10.1186/s40170-026-00425-6

Keywords: Ovarian Cancer, Constraint-based Modelling, TPI1, Metabolic Modelling, Gene Knockdown, RNA Sequencing, Cancer Metabolism, Computational Biology, Transcriptome-driven, constraint-based, modelling, reveals

News Source: Nathaniel Bowman. (November 10, 2026). Computational Model Identifies TPI1 as Ovarian Cancer Target. Scienmag.

Tags: cancer metabolismcomputational biologyconstraint-basedConstraint-based Modellinggene knockdownMetabolic ModellingmodellingOvarian cancerrevealsRNA sequencingTPI1Transcriptome-driven
Share12Tweet7Share2ShareShareShare1

Related Posts

Cancer Metastasectomy Framework Calibrates Surgical Benefit by Histology and Treatment State

Cancer Metastasectomy Framework Calibrates Surgical Benefit by Histology and Treatment State

November 17, 2026
Gut Microbiota Regulates Drug Metabolism but Clinical Biomarkers Still Lack Validation

Gut Microbiota Regulates Drug Metabolism but Clinical Biomarkers Still Lack Validation

November 17, 2026

Narrative Review Outlines Framework Aligning Dysmenorrhea Management With Individual Fertility Goals

November 17, 2026

Rare Palmar Basal Cell Carcinoma Mimics Vascular Hemangioma in Case Report

November 17, 2026

POPULAR NEWS

  • Vitamin A Deficiency Persists in Congolese Children Despite Long-Term Supplementation Efforts

    Vitamin A Deficiency Persists in Congolese Children Despite Long-Term Supplementation Efforts

    29 shares
    Share 12 Tweet 7
  • Veterinarians Identify Twelve Defences to Improve Medication Safety in Sows

    29 shares
    Share 12 Tweet 7
  • Ascending Aorta Shows Marked Elongation Before Dissection Despite Only Moderate Dilatation

    29 shares
    Share 12 Tweet 7
  • Rural Australian Hospital Study Links Insulin and Polypharmacy to Medication Readmissions

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Cancer Metastasectomy Framework Calibrates Surgical Benefit by Histology and Treatment State

Gut Microbiota Regulates Drug Metabolism but Clinical Biomarkers Still Lack Validation

Narrative Review Outlines Framework Aligning Dysmenorrhea Management With Individual Fertility Goals

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.